{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:15:20Z","timestamp":1788869720777,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57263-1","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:59:21Z","timestamp":1781841561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K\/AKT signaling pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Li","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangrui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"57263_CR1","doi-asserted-by":"publisher","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","volume":"1","author":"H Dimaras","year":"2015","unstructured":"Dimaras, H. et al. Retinoblastoma. Nat Rev Dis Primers. 1, 15021 (2015).","journal-title":"Nat Rev Dis Primers."},{"issue":"9","key":"57263_CR2","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ophtha.2021.01.024","volume":"128","author":"AW Stacey","year":"2021","unstructured":"Stacey, A. W. et al. Incidence of retinoblastoma has increased: results from 40 European Countries. Ophthalmology 128(9), 1369\u20131371 (2021).","journal-title":"Ophthalmology"},{"issue":"8","key":"57263_CR3","doi-asserted-by":"publisher","first-page":"e1128","DOI":"10.1016\/S2214-109X(22)00250-9","volume":"10","author":"The Global Retinoblastoma Outcome Study","year":"2022","unstructured":"The Global Retinoblastoma Outcome Study. a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 10(8), e1128\u2013e1140 (2022).","journal-title":"Lancet Glob Health."},{"issue":"1","key":"57263_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12964-023-01223-z","volume":"21","author":"VV Byroju","year":"2023","unstructured":"Byroju, V. V., Nadukkandy, A. S., Cordani, M. & Kumar, L. D. Retinoblastoma: present scenario and future challenges. Cell Commun. Signal. 21(1), 226 (2023).","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"57263_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.18240\/ijo.2023.06.20","volume":"16","author":"L Koochakzadeh","year":"2023","unstructured":"Koochakzadeh, L. et al. Epidemiological aspect of retinoblastoma in the world: a review of recent advance studies. Int. J. Ophthalmol. 16(6), 962\u2013968 (2023).","journal-title":"Int. J. Ophthalmol."},{"issue":"7","key":"57263_CR6","first-page":"611","volume":"328","author":"HD Larkin","year":"2022","unstructured":"Larkin, H. D. Retinoblastoma especially deadly in children in low-income countries. JAMA 328(7), 611 (2022).","journal-title":"JAMA"},{"issue":"5","key":"57263_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ophtha.2020.09.032","volume":"128","author":"AS Tomar","year":"2021","unstructured":"Tomar, A. S. et al. Global retinoblastoma treatment outcomes: association with national income level. Ophthalmology 128(5), 740\u2013753 (2021).","journal-title":"Ophthalmology"},{"issue":"5","key":"57263_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamaoncol.2019.6716","volume":"6","author":"ID Fabian","year":"2020","unstructured":"Fabian, I. D. et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 6(5), 685\u2013695 (2020).","journal-title":"JAMA Oncol."},{"issue":"6","key":"57263_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4103\/IJO.IJO_2414_23","volume":"72","author":"A Nag","year":"2024","unstructured":"Nag, A. & Khetan, V. Retinoblastoma - a comprehensive review, update and recent advances. Indian J. Ophthalmol. 72(6), 778\u2013788 (2024).","journal-title":"Indian J. Ophthalmol."},{"issue":"2","key":"57263_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2024.100058","volume":"13","author":"M Zhou","year":"2024","unstructured":"Zhou, M. et al. Recent progress in retinoblastoma: pathogenesis, presentation, diagnosis and management. Asia Pac. J. Ophthalmol. (Phila). 13(2), 100058 (2024).","journal-title":"Asia Pac. J. Ophthalmol. (Phila)."},{"issue":"11","key":"57263_CR11","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","volume":"68","author":"D Ancona-Lezama","year":"2020","unstructured":"Ancona-Lezama, D., Dalvin, L. A. & Shields, C. L. Modern treatment of retinoblastoma: a 2020 review. Indian J. Ophthalmol. 68(11), 2356\u20132365 (2020).","journal-title":"Indian J. Ophthalmol."},{"issue":"9","key":"57263_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2352-4642(23)00141-4","volume":"7","author":"X Wen","year":"2023","unstructured":"Wen, X. et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Lancet Child Adolesc. Health. 7(9), 613\u2013620 (2023).","journal-title":"Lancet Child Adolesc. Health."},{"issue":"8","key":"57263_CR13","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.oret.2021.05.007","volume":"5","author":"L Lumbroso-Le Rouic","year":"2021","unstructured":"Lumbroso-Le Rouic, L. et al. Selective ophthalmic artery chemotherapy with melphalan in the management of unilateral retinoblastoma: a prospective study. Ophthalmol. Retina. 5(8), e30\u2013e37 (2021).","journal-title":"Ophthalmol. Retina."},{"key":"57263_CR14","doi-asserted-by":"crossref","unstructured":"Solera-de-Andr\u00e9s, C., Spang-Valencia, P., Peralta-Calvo, J. Severe visual loss and ocular complications after intra-arterial chemotherapy for retinoblastoma. Br J Ophthalmol. (2025).","DOI":"10.1136\/bjo-2025-328113"},{"issue":"2","key":"57263_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.rxeng.2025.02.001","volume":"67","author":"V Pai","year":"2025","unstructured":"Pai, V. et al. An updated review of intra-arterial chemotherapy for retinoblastoma. Radiologia (Engl. Ed). 67(2), 162\u2013175 (2025).","journal-title":"Radiologia (Engl. Ed)."},{"issue":"7","key":"57263_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/medicina61071219","volume":"61","author":"CA Mart\u00ednez Arce","year":"2025","unstructured":"Mart\u00ednez Arce, C. A., Villegas, V. M., Di Nicola, M., Williams, B. K. Jr. & Murray, T. G. Update on retinoblastoma therapies. Medicina (Kaunas). 61(7), 1219 (2025).","journal-title":"Medicina (Kaunas)."},{"issue":"5","key":"57263_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/ICU.0000000000001155","volume":"36","author":"EM Ramos-D\u00e1vila","year":"2025","unstructured":"Ramos-D\u00e1vila, E. M., Williams, B. K. Jr. & Di Nicola, M. Managing retinoblastoma in 2025. Curr. Opin. Ophthalmol. 36(5), 414\u2013426 (2025).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"57263_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.977374","volume":"16","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Research progress on the pharmacological effects of matrine. Front. Neurosci. 16, 977374 (2022).","journal-title":"Front. Neurosci."},{"issue":"7","key":"57263_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.410","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Rebalancing TGF-\u03b2\/Smad7 signaling via compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis. Clin. Transl. Med. 11(7), e410 (2021).","journal-title":"Clin. Transl. Med."},{"key":"57263_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116778","volume":"317","author":"C Li","year":"2023","unstructured":"Li, C. et al. Adjunctive effect of compound Kushen injection for cancer: an overview of systematic reviews. J. Ethnopharmacol. 317, 116778 (2023).","journal-title":"J. Ethnopharmacol."},{"key":"57263_CR21","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.2147\/CMAR.S563211","volume":"17","author":"Z Xiong","year":"2025","unstructured":"Xiong, Z. & Pu, J. Matrine and its derivatives: multi-pathway regulation in cancer therapy. Cancer Manage. Res. 17, 3285\u20133297 (2025).","journal-title":"Cancer Manage. Res."},{"key":"57263_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155165","volume":"122","author":"J Jin","year":"2024","unstructured":"Jin, J. et al. Matrine induces ferroptosis in cervical cancer through activation of piezo1 channel. Phytomedicine 122, 155165 (2024).","journal-title":"Phytomedicine"},{"key":"57263_CR23","doi-asserted-by":"crossref","unstructured":"Chen, M. H. et al. Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer. Pharmacol Res. 171, 105778.","DOI":"10.1016\/j.phrs.2021.105778"},{"issue":"1","key":"57263_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/ijms25010540","volume":"25","author":"Z Feng","year":"2023","unstructured":"Feng, Z. et al. Matrine targets BTF3 to inhibit the growth of canine mammary tumor cells. Int. J. Mol. Sci. 25(1), 540 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"57263_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cbi.2019.05.030","volume":"308","author":"G Chi","year":"2019","unstructured":"Chi, G., Xu, D., Zhang, B. & Yang, F. Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075\/BCL-9. Chem. Biol. Interact. 308, 198\u2013205 (2019).","journal-title":"Chem. Biol. Interact."},{"key":"57263_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116738","volume":"175","author":"X Li","year":"2024","unstructured":"Li, X. et al. Matrine induces autophagic cell death by triggering ROS\/AMPK\/mTOR axis and apoptosis in multiple myeloma. Biomed. Pharmacother. 175, 116738 (2024).","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"57263_CR27","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/jcb.29469","volume":"121","author":"ZM Liu","year":"2020","unstructured":"Liu, Z. M., Yang, X. L., Jiang, F., Pan, Y. C. & Zhang, L. Matrine involves in the progression of gastric cancer through inhibiting miR-93-5p and upregulating the expression of target gene AHNAK. J. Cell Biochem. 121(3), 2467\u20132477 (2020).","journal-title":"J. Cell Biochem."},{"key":"57263_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114914","volume":"286","author":"F Chen","year":"2022","unstructured":"Chen, F., Pan, Y., Xu, J., Liu, B. & Song, H. Research progress of matrine\u2019s anticancer activity and its molecular mechanism. J. Ethnopharmacol. 286, 114914 (2022).","journal-title":"J. Ethnopharmacol."},{"issue":"24","key":"57263_CR29","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1038\/s44318-024-00290-3","volume":"43","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Nuclear receptor E75\/NR1D2 promotes tumor malignant transformation by integrating Hippo and Notch pathways. Embo J. 43(24), 6336\u20136363 (2024).","journal-title":"Embo J."},{"key":"57263_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154909","volume":"116","author":"D Luo","year":"2023","unstructured":"Luo, D. et al. Sophflarine A, a novel matrine-derived alkaloid from Sophora flavescens with therapeutic potential for non-small cell lung cancer through ROS-mediated pyroptosis and autophagy. Phytomedicine 116, 154909 (2023).","journal-title":"Phytomedicine"},{"key":"57263_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari, D., Patni, P., Bishayee, A., Sah, A. N. & Bishayee, A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 80, 1\u201317 (2022).","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"57263_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6(1), 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"57263_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/19768354.2018.1561516","volume":"23","author":"SH Kim","year":"2019","unstructured":"Kim, S. H. et al. \u03b2(2)-Adrenergic receptor (\u03b2(2)-AR) agonist formoterol suppresses differentiation of L6 myogenic cells by blocking PI3K-AKT pathway. Anim. Cells Syst. (Seoul). 23(1), 18\u201325 (2019).","journal-title":"Anim. Cells Syst. (Seoul)."},{"issue":"1","key":"57263_CR34","doi-asserted-by":"publisher","first-page":"12351","DOI":"10.1038\/s41598-023-39655-9","volume":"13","author":"S Wei","year":"2023","unstructured":"Wei, S. et al. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K\/AKT pathway. Sci. Rep. 13(1), 12351 (2023).","journal-title":"Sci. Rep."},{"issue":"9","key":"57263_CR35","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1002\/cam4.1720","volume":"7","author":"W Zhou","year":"2018","unstructured":"Zhou, W. et al. Matrine induces senescence of human glioblastoma cells through suppression of the IGF1\/PI3K\/AKT\/p27 signaling pathway. Cancer Med. 7(9), 4729\u20134743 (2018).","journal-title":"Cancer Med."},{"issue":"1","key":"57263_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/aps.2016.104","volume":"38","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K\/AKT signaling pathways. Acta Pharmacol. Sin. 38(1), 120\u2013132 (2017).","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57263-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:02:50Z","timestamp":1788868970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57263-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57263-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The animal experimental protocols gained approval from the Management and Use Committee of Experimental Animals of Chongqing Medical University (Approval Number: IAUC-CQMU-2024\u20130154), and the relevant animal welfare regulations were followed.","order":2,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"28039"}}